Pharmacogenomics_Paediatric

Gene: CYP2C9

Green List (high evidence)

CYP2C9 (cytochrome P450 family 2 subfamily C member 9)
EnsemblGeneIds (GRCh38): ENSG00000138109
EnsemblGeneIds (GRCh37): ENSG00000138109
OMIM: 601130, Gene2Phenotype
CYP2C9 is in 2 panels

2 reviews

David Metz (Royal Children's Hospital)

25099164
If CYP2C9 IM, consider 25% reduction starting dose (moderate recommendation).
If CYP2C9 PM, consider 50% reduction starting dose phenytoin (strong recommendation).
Created: 21 Sep 2020, 1:01 a.m. | Last Modified: 21 Sep 2020, 1:18 a.m.
Panel Version: 0.50
(32189324)
Note poor metabolizer status has increased exposure (and possible sensitivity) to certain NSAIDs.
"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen, and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity."
Probably not sufficient evidence to test for CYP2C9 alone, however if information available may be worth noting.
Created: 14 Aug 2020, 1:28 a.m. | Last Modified: 14 Aug 2020, 1:28 a.m.
Panel Version: 0.33
In vivo, metabolic activity over 1y age is same as adults (18406467).
Created: 14 Aug 2020, 12:33 a.m. | Last Modified: 14 Aug 2020, 12:33 a.m.
Panel Version: 0.33

Phenotypes
Phenytoin metabolism - increased risk toxicities

Publications

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Green List (high evidence)

Activity levels of CYP2C9 are at 1-2% of adult values in the fetus during the first trimester. These levels gradually increase to 30% of adult values at term. There is a high variability in these levels during the first 5 months of life, with levels eventually approaching adult values somewhere between 5 months and 2 years of age.
Created: 1 Aug 2020, 1:52 a.m. | Last Modified: 1 Aug 2020, 1:52 a.m.
Panel Version: 0.19
Sources: Expert list
Created: 31 Jul 2020, 10:12 a.m.

Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Phenotypes
Warfarin sensitivity, MIM# 122700; Phenytoin

Publications

Details

Mode of Inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Sources
  • Expert Review Green
  • Expert list
Phenotypes
  • Warfarin sensitivity, MIM# 122700
  • Phenytoin
OMIM
601130
Clinvar variants
Variants in CYP2C9
Penetrance
None
Publications
Panels with this gene

History Filter Activity

1 Aug 2020, Gel status: 3

Set publications

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Publications for gene: CYP2C9 were set to 25099164

1 Aug 2020, Gel status: 3

Set publications

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Publications for gene: CYP2C9 were set to

31 Jul 2020, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: cyp2c9 has been classified as Green List (High Evidence).

31 Jul 2020, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: cyp2c9 has been classified as Green List (High Evidence).

31 Jul 2020, Gel status: 1

Created, Added New Source, Set mode of inheritance, Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

gene: CYP2C9 was added gene: CYP2C9 was added to Pharmacogenomics_Paediatric. Sources: Expert list Mode of inheritance for gene: CYP2C9 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted Phenotypes for gene: CYP2C9 were set to Warfarin sensitivity, MIM# 122700; Phenytoin Review for gene: CYP2C9 was set to GREEN